Image
|
Figure Caption
Figure 4
KPT−8602 reduces osteopontin serum levels in D2-mdx mice. Osteopontin (OPN) in circulating serum levels was assessed by ELISA assay. KPT−8602 (5x/week) treatment significantly reduced osteopontin levels compared to vehicle-treated D2-mdx, demonstrating levels comparable to WT mice (data is presented as mean ± SEM, n = 4–5 mice per cohort; * p < 0.05, ** p < 0.01; one-way ANOVA with Tukey’s HSD test).
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and
ZFIN has permission only to display this image to its users.
Additional permissions should be obtained from the applicable author or publisher of the image.
Full text @ Biomedicines